August 29, 2017 5:50pm

 

… At some of these prices are too inflated as investors increase their exposure to immune-oncology after the KITE news broke

Buy-out significance of the shooting stars is limited by partnered programs but, thanks for the upside

 

… By Friday, some skyrockets will have expended their powder

I’d be focused on Celgene (CELG) with current partners (BLUE and JUNO) and stands to benefit from the GILD/KITE headlines

 

Pre-open indications: 3 hits and 3 miss:

 

It’s called premium content for a reason … I define insight  from a real-time perspective discussing equity share pricing, attractiveness and support levels as stock pricing changes by the hour … if not the minute!

Others don’t even come close!

 

I answer one question, in which company should investors commit and keep their money.

 

 

Tuesday’s results have implications to Wednesday’s sector activity as a daily report may say little or a lot and it serves as insurance that all indications are being examined and evaluated!

 

 

Henry’omics:

From the pre-open’s investor’s newsletter “…, expect a reversal.  Yesterday … KITE jump big on all cash buy-out and as the Labor Day weekend approaches.”

  • Stocks closed higher as the “Street” shook-off US-North Korea tensions. U.S. stocks initially sold off before regaining their footing.

The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market, briefly rose more than 20% before holding about 4 percent higher.

  • After all the hoopla yesterday, the major U.S. stock benchmarks continue to digest the August downturn; the year’s most technically damaging to date.  In the process, the S&P 500 has failed its latest retest of major resistance — S&P 2,453 — amid potentially consequential emerging trends across asset classes.

As I mentioned yesterday as well, the index has violated major support — S&P 2,453 — and observed this area as resistance … which I also mentioned, as the NASDAQ has staged an extended late-August retest of the 50-day moving average.

 

Get ready for a … difficult September!

Broadly speaking, the August consolidation phase remains underway against a persistently uneven technical backdrop.

On a headline basis, the NASDAQ has stalled near the 50-day moving average, while the S&P 500 remains capped by well-documented overhead. <MarketWatch>

 

 

Pre-open indications: 3 hits and 3 miss:

  • Applied Genetic Technologies (AGTC) closed $0.06 – hit;
  • Bellicum Pharmaceuticals (BLCM) closed up +$0.68 – miss;
  • bluebird bio (BLUE) closed down -$3.90 – hit;
  • Cellectis SA (CLLS) closed down -$0.79 – hit;
  • Juno Therapeutics (JUNO) closed up +$7.33 – miss;
  • Sangamo Therapeutics (SGMO) closed up +$1.30 – miss;

 

 

The advance/decline line scenario of 43 SCGT & RT covered companies:   

·         The first hour was positive with an A/DL of 25/14 and 4 flats;

·         The mid-day was positive with an A/DL of 24/16 and 3 flat;

·         The close was positive  with an A/DL of 24/16 and 3 flat;

 

 

Daily analytics:

U.S. stocks closed higher on Tuesday, with major indexes recovering from early losses that came after North Korea launched a missile over Japanese airspace, the latest instance of geopolitical tension with the country.

·         The Dow rose 57 points, or 0.3%, to 21,865.

·         The S&P 500 rose 2 points, or 0.1%, to 2,446.

·         The NASDAQ ended up 19 points to 6,302, a rise of 0.3%.

 

 

The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market; Tuesday traded at 10.71, up +3.45% …

  • Monday traded at 11.34, up +0.09% following Friday trading at 11.24, down -8.09% after Thursday traded 12.23, down -0.16% … after Wednesday traded at 11.91, up +4.93% after last Tuesday traded at 11.40, down -13.57%

 

 

Welcome to another day of the sector’s roller coaster …

… The iShares Russell 2000 (IWM) indicated:

·         Tuesday was up +0.02%

·         Monday +0.44%

·         Friday +0.29%

·         Thursday +0.32%

·         Wednesday -0.18%

·         Last Tuesday+1.08%

… The iShares NASDAQ Biotechnology (IBB) indicated:

·         Tuesday was up +0.29%

·         Monday +1.88%

·         Friday -0.58%

·         Thursday +1.20%

·         Wednesday -0.44%

·         Last Tuesday +1.92%

 

 

The count - decliners versus gainers:

……. look at the differences in the spreads as decliners jump and %

·         Tuesday’s decliners ranged from -0.06% <KITE -$0.10> to -7.49% <QURE -$0.64> in 16  equities;

·         Monday’s decliners ranged from -0.06% <MDXG -$0.01> to -5% <CUR -$0.06> in 14  equities;

·         Friday’s decliners ranged from -0.24% <BCLI -$0.01> to -9.89% <OPXA +$0.09> in 21  equities;

·         Thursday’s decliners ranged from -1.35% <RENE.L -$0.025> to -9.78% <IMUC -$0.04> in 11 equities;

·         Wednesday’s decliners ranged from -0.31% <CYTX -$0.001> to -5.13% <RENE.L -$0.10> in 18 equities;

·         Last Tuesday’s decliners ranged from -0.57% <HSGX -$0.01> to -5.27% <BSTG -$0.0148> in 11 equities;

 

Versus

… Look at the percentage’s (%) and spreads …

·         Tuesday’s gainers ranged from +0.50% <OSIR +$0.03> to +20.09% <JUNO +$7.33> in 24 equities;

·         Monday’s gainers ranged from +0.48% <RGNX +$0.10> to +28% <KITE +$38.95> in 21 equities;

·         Friday’s gainers ranged from +0.47% <SGMO +$0.05> to +8.70% <CYTX +$0.03> in 17 equities;

·         Thursday’s gainers ranged from +0.60% <HSGX +$0.01> to +9.09% <ADVM +$0.23> in 26 equities;

·         Wednesdays gainers ranged from +0.08% <CLLS +$0.02> to +25.24% <BSTG +$0.067> in 21 equities;

·         Last Tuesday’s gainers ranged from +0.33% <OSIR +$0.02> to +20.25% <OPXA +$0.16> in 28 equities;

 

 

Some of MY working trend lines or indications:

… The greatest volume to the downside:  KITE, NWBO, IMUC, BLUE and BSTG

… Upside volume was weighted to:  JUNO, SGMP, CUR, VCEL and MDXG

… Biggest $ downside:  BLUE, CLLS, QURE, RGNX and ONCE

… Largest $ upside:  JUNO, SGMO, XON, BLCM and AXGN

… Flat:  CYTX, ONVO and ATHX

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.